Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from PharmaTher Holdings Ltd ( (TSE:PHRM) ).
PharmaTher Holdings Ltd. has resubmitted its application to the FDA for the approval of Ketamine, addressing minor deficiencies previously noted by the agency. The company anticipates FDA approval in the second quarter of 2025, which could significantly impact the Ketamine shortage in the U.S. and enhance its use in treating various medical conditions. This move positions PharmaTher as a key player in addressing the Ketamine shortage and unlocking its potential for broader medical applications.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on developing innovative solutions for unmet medical needs. The company is particularly involved in the pharmaceutical potential of Ketamine, a drug known for its use in anesthesia and pain relief.
YTD Price Performance: -7.84%
Average Trading Volume: 189,737
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.57M
For a thorough assessment of PHRM stock, go to TipRanks’ Stock Analysis page.